Clinical Studies

FDA approval for a rare disease treatment is not a finish line. It is one important milestone in a broader commitment to working with a rare disease community to meet their needs respectfully and responsively. We remain focused on generating additional data to support the safe and effective use of therapies beyond the evidence that supported FDA approval. To that end, we support ongoing research to more fully characterize our product in real world settings.